These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Mechanism of Action of Miltefosine on Leishmania donovani Involves the Impairment of Acidocalcisome Function and the Activation of the Sphingosine-Dependent Plasma Membrane Ca Pinto-Martinez AK; Rodriguez-Durán J; Serrano-Martin X; Hernandez-Rodriguez V; Benaim G Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061745 [No Abstract] [Full Text] [Related]
11. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India. Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296 [TBL] [Abstract][Full Text] [Related]
12. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain. Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765 [TBL] [Abstract][Full Text] [Related]
13. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445 [TBL] [Abstract][Full Text] [Related]
14. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis. Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196 [TBL] [Abstract][Full Text] [Related]
15. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome. Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089 [TBL] [Abstract][Full Text] [Related]
16. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history. Reimão JQ; Pita Pedro DP; Coelho AC Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449 [TBL] [Abstract][Full Text] [Related]
17. Studies on the antileishmanial mechanism of action of the arylimidamide DB766: azole interactions and role of CYP5122A1. Pandharkar T; Zhu X; Mathur R; Jiang J; Schmittgen TD; Shaha C; Werbovetz KA Antimicrob Agents Chemother; 2014 Aug; 58(8):4682-9. PubMed ID: 24890590 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis. Coelho AC; Trinconi CT; Costa CH; Uliana SR PLoS Negl Trop Dis; 2014 Jul; 8(7):e2999. PubMed ID: 25033218 [TBL] [Abstract][Full Text] [Related]
19. In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization. Shaw CD; Lonchamp J; Downing T; Imamura H; Freeman TM; Cotton JA; Sanders M; Blackburn G; Dujardin JC; Rijal S; Khanal B; Illingworth CJ; Coombs GH; Carter KC Mol Microbiol; 2016 Mar; 99(6):1134-48. PubMed ID: 26713880 [TBL] [Abstract][Full Text] [Related]
20. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages. Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]